Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules.

Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC 3rd, Morris LGT, Odell M, Scharpf J, Shaha A, Shin JJ, Shonka DC Jr, Thompson GB, Tuttle RM, Urken ML, Wiseman SM, Wong RJ, Randolph G.

Head Neck. 2019 Apr;41(4):843-856. doi: 10.1002/hed.25526. Epub 2018 Dec 18.

PMID:
30561068
2.

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.

PMID:
30545990
3.

Summary of the Third World Congress on Thyroid Cancer.

McIver B, Freeman J, Shah JP, Shaha AR, Haugen B, Cohen E, Witterick IJ, Randolph GW.

Thyroid. 2018 Nov;28(11):1401-1405. doi: 10.1089/thy.2018.0616. No abstract available.

PMID:
30303467
4.

Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules.

Valderrabano P, Khazai L, Thompson ZJ, Otto KJ, Hallanger-Johnson JE, Chung CH, Centeno BA, McIver B.

JAMA Otolaryngol Head Neck Surg. 2018 Sep 1;144(9):788-795. doi: 10.1001/jamaoto.2018.1070.

PMID:
30027226
5.

AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.

Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, Duh QY, Wong R, Sabra MM, Fagin JA, McIver B, Bernet VJ, Harrell RM, Busaidy N, Cibas ES, Faquin WC, Sadow P, Baloch Z, Shindo M, Orloff L, Davies L, Randolph GW.

Head Neck. 2018 Sep;40(9):1881-1888. doi: 10.1002/hed.25141. Epub 2018 Jun 26.

6.

Thyroid Nodules with Indeterminate Cytology: Utility of the American Thyroid Association Sonographic Patterns for Cancer Risk Stratification.

Valderrabano P, McGettigan MJ, Lam CA, Khazai L, Thompson ZJ, Chung CH, Centeno BA, McIver B.

Thyroid. 2018 Aug;28(8):1004-1012. doi: 10.1089/thy.2018.0085. Epub 2018 Jul 17.

PMID:
29848195
7.

Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules.

Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Chung CH, Centeno BA, McIver B.

Head Neck. 2018 Aug;40(8):1812-1823. doi: 10.1002/hed.25165. Epub 2018 Apr 6.

PMID:
29624786
8.

A thyrotropin-secreting pituitary adenoma treated with radiosurgery: Long-term outcomes.

Araujo Castro M, McIver B, Valderrabano P.

Endocrinol Diabetes Nutr. 2018 Apr;65(4):237-238. doi: 10.1016/j.endinu.2017.12.007. Epub 2018 Feb 6. English, Spanish. No abstract available.

PMID:
29426625
9.

Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.

Valderrabano P, Khazai L, Thompson ZJ, Sharpe SC, Tarasova VD, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B.

Thyroid. 2018 Feb;28(2):210-219. doi: 10.1089/thy.2017.0419. Epub 2017 Dec 21.

PMID:
29160163
10.

Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.

Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Wittich MAN, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M, Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC, Bible KC.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4506-4514. doi: 10.1210/jc.2017-01180.

PMID:
29029287
11.

Evaluation and Management of Indeterminate Thyroid Nodules: The Revolution of Risk Stratification Beyond Cytological Diagnosis.

Valderrabano P, McIver B.

Cancer Control. 2017 Oct-Dec;24(5):1073274817729231. doi: 10.1177/1073274817729231. Review.

12.

Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach.

Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B.

Thyroid. 2017 Oct;27(10):1277-1284. doi: 10.1089/thy.2017.0221. Epub 2017 Sep 14.

13.

Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement.

Agrawal N, Evasovich MR, Kandil E, Noureldine SI, Felger EA, Tufano RP, Kraus DH, Orloff LA, Grogan R, Angelos P, Stack BC Jr, McIver B, Randolph GW.

Head Neck. 2017 Jul;39(7):1269-1279. doi: 10.1002/hed.24715. Epub 2017 Apr 27. Review.

PMID:
28449244
14.

Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.

Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, Hallanger-Johnson JE, Otto KJ, Rogers KD, Centeno BA, McIver B.

Endocr Relat Cancer. 2017 Mar;24(3):127-136. doi: 10.1530/ERC-16-0512. Epub 2017 Jan 19.

PMID:
28104680
15.

Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for Malignancy.

Valderrabano P, Montilla-Soler J, Mifsud M, Leon M, Centeno B, Khazai L, Padhya T, McCaffrey T, Russell J, McIver B, Otto K.

Thyroid. 2016 Sep;26(9):1300-7. doi: 10.1089/thy.2015.0654. Epub 2016 Aug 9.

PMID:
27324615
16.

New American Thyroid Association Sonographic Patterns for Thyroid Nodules Perform Well in Medullary Thyroid Carcinoma: Institutional Experience, Systematic Review, and Meta-Analysis.

Valderrabano P, Klippenstein DL, Tourtelot JB, Ma Z, Thompson ZJ, Lilienfeld HS, McIver B.

Thyroid. 2016 Aug;26(8):1093-100. doi: 10.1089/thy.2016.0196. Epub 2016 Jul 8. Review.

PMID:
27267210
17.

Vitamin D and Melanoma: What Do We Tell Our Patients?

Sondak VK, McIver B, Kanetsky PA.

J Clin Oncol. 2016 May 20;34(15):1713-4. doi: 10.1200/JCO.2016.66.5240. Epub 2016 Apr 4. No abstract available.

PMID:
27044934
18.

Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests.

Valderrabano P, Leon ME, Centeno BA, Otto KJ, Khazai L, McCaffrey JC, Russell JS, McIver B.

Eur J Endocrinol. 2016 May;174(5):621-9. doi: 10.1530/EJE-15-1163. Epub 2016 Feb 22.

PMID:
26903551
19.

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer.

Fordham BA, Kerr C, de Freitas HM, Lloyd AJ, Johnston K, Pelletier CL, Tremblay G, Forsythe A, McIver B, Cohen EE.

Patient Prefer Adherence. 2015 Nov 3;9:1561-72. doi: 10.2147/PPA.S90425. eCollection 2015.

20.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: TIMING OF MULTIPLE ENDOCRINE NEOPLASIA THYROIDECTOMY AND EXTENT OF CENTRAL NECK LYMPHADENECTOMY.

Lairmore TC, Diesen D, Goldfarb M, Milas M, Ying AK, Sharma J, McIver B, Wong RJ, Randolph G; AACE Endocrine Surgery Scientific Committee.

Endocr Pract. 2015 Jul;21(7):839-47. doi: 10.4158/EP14463.DSCR. Review. No abstract available.

PMID:
26172129
21.

Molecular Assays in Cytopathology for Thyroid Cancer.

Valderrabano P, Zota VE, McIver B, Coppola D, Leon ME.

Cancer Control. 2015 Apr;22(2):152-7. Review.

PMID:
26068759
22.
23.

Clinical consequences of a change in anti-thyroglobulin antibody assays during the follow-up of patients with differentiated thyroid cancer.

Donegan D, McIver B, Algeciras-Schimnich A.

Endocr Pract. 2014 Oct;20(10):1032-6. doi: 10.4158/EP13499.OR.

PMID:
24793919
24.

An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.

McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H.

J Clin Endocrinol Metab. 2014 Nov;99(11):4069-77. doi: 10.1210/jc.2013-3584. Epub 2014 Apr 29.

PMID:
24780044
25.

Summary of proceedings of the second World Congress on Thyroid Cancer.

Czerwonka L, Freeman J, McIver B, Randolph GW, Shah JP, Shaha AR, Sherman SI, Tuttle RM, Witterick IJ.

Head Neck. 2014 Jul;36(7):917-20. doi: 10.1002/hed.23631. Epub 2014 Apr 25.

PMID:
24677329
26.

Evaluating thyroid nodules in the information age: new technologies, new opportunities, new challenges.

McIver B.

Endocr Pract. 2014 Apr;20(4):370-3. doi: 10.4158/EP14105.CO. No abstract available.

PMID:
24641936
27.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C; Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium.

J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25.

28.

RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Smallridge RC, Chindris AM, Asmann YW, Casler JD, Serie DJ, Reddi HV, Cradic KW, Rivera M, Grebe SK, Necela BM, Eberhardt NL, Carr JM, McIver B, Copland JA, Thompson EA.

J Clin Endocrinol Metab. 2014 Feb;99(2):E338-47. doi: 10.1210/jc.2013-2792. Epub 2013 Dec 2.

29.

A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience.

Call JA, Caudill JS, McIver B, Foote RL.

Rare Tumors. 2013 Jul 12;5(3):e37. doi: 10.4081/rt.2013.e37. eCollection 2013.

30.

Postoperative surveillance of thyroid carcinoma.

McIver B.

Oral Oncol. 2013 Jul;49(7):684-8. doi: 10.1016/j.oraloncology.2013.03.436. Epub 2013 May 23. Review. No abstract available.

PMID:
23706807
31.

Evaluation of the thyroid nodule.

McIver B.

Oral Oncol. 2013 Jul;49(7):645-53. doi: 10.1016/j.oraloncology.2013.03.435. Epub 2013 May 23. No abstract available. Erratum in: Oral Oncol. 2013 Nov;49(11):1088.

PMID:
23706806
32.

Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis.

Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM.

Thyroid. 2013 Apr;23(4):449-55. doi: 10.1089/thy.2012.0156. Review.

PMID:
23067375
33.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

J Oncol Pract. 2012 May;8(3 Suppl):e1s-5s. doi: 10.1200/JOP.2011.000496.

34.

The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology.

Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B.

Thyroid. 2012 Oct;22(10):996-1001. doi: 10.1089/thy.2012.0180. Epub 2012 Aug 8.

35.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

Am J Manag Care. 2012 May 1;18(5):e162-7.

36.

Prognostic factors for thyroid carcinoma originating from follicular cells.

Ito Y, McIver B, Besic N, Agarwal A.

J Thyroid Res. 2012;2012:920631. doi: 10.1155/2012/920631. Epub 2011 Dec 27. No abstract available.

37.

The Putative PAX8/PPARĪ³ Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of Micro-RNA-122 and Dominant-Negative PPARĪ³ Activity.

Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, Grebe SK, Eberhardt NL.

Genes Cancer. 2011 Jan;2(1):46-55. doi: 10.1177/1947601911405045.

38.

Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976-2008.

Fatourechi MM, Hay ID, McIver B, Sebo TJ, Fatourechi V.

Thyroid. 2011 Jul;21(7):765-72. doi: 10.1089/thy.2010.0453. Epub 2011 May 13.

PMID:
21568724
39.

Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.

Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC.

Thyroid. 2011 Jan;21(1):25-30. doi: 10.1089/thy.2010.0220. Epub 2010 Dec 16.

PMID:
21162687
40.

Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma.

Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Bhattacharya A, Lea R, Grebe SK.

Pathology. 2010;42(6):524-33. doi: 10.3109/00313025.2010.508780.

PMID:
20854070
41.

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium.

Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17.

42.

Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.

Marlow LA, D'Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL, Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S, Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2010 Dec;95(12):5338-47. doi: 10.1210/jc.2010-1421. Epub 2010 Sep 1. Erratum in: J Clin Endocrinol Metab. 2013 Oct;98(10):4213. J Clin Endocrinol Metab. 2013 Nov;98(11):4546.

43.

Graves' disease after unilateral Riedel's thyroiditis.

McIver B, Fatourechi MM, Hay ID, Fatourechi V.

J Clin Endocrinol Metab. 2010 Jun;95(6):2525-6. doi: 10.1210/jc.2009-2609. No abstract available.

PMID:
20525902
44.

Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis.

Algeciras-Schimnich A, Milosevic D, McIver B, Flynn H, Reddi HV, Eberhardt NL, Grebe SK.

Clin Chem. 2010 Mar;56(3):391-8. doi: 10.1373/clinchem.2009.134015. Epub 2010 Jan 7.

45.

The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

Eberhardt NL, Grebe SK, McIver B, Reddi HV.

Mol Cell Endocrinol. 2010 May 28;321(1):50-6. doi: 10.1016/j.mce.2009.10.013. Epub 2009 Oct 31. Review.

46.

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM.

Thyroid. 2009 Nov;19(11):1167-214. doi: 10.1089/thy.2009.0110. Erratum in: Thyroid. 2010 Jun;20(6):674-5. Thyroid. 2010 Aug;20(8):942. Hauger, Bryan R [corrected to Haugen, Bryan R].

47.

Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.

Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK.

J Clin Endocrinol Metab. 2009 Dec;94(12):5001-9. doi: 10.1210/jc.2009-1349. Epub 2009 Oct 22.

PMID:
19850689
48.

Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA.

Cancer Res. 2009 Feb 15;69(4):1536-44. doi: 10.1158/0008-5472.CAN-08-3718. Epub 2009 Feb 10.

49.

Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period.

Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ, Goellner JR.

Surgery. 2008 Dec;144(6):980-7; discussion 987-8. doi: 10.1016/j.surg.2008.08.035.

PMID:
19041007
50.

The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer.

Placzkowski KA, Reddi HV, Grebe SK, Eberhardt NL, McIver B.

PPAR Res. 2008;2008:672829. doi: 10.1155/2008/672829. Epub 2008 Oct 29.

Supplemental Content

Loading ...
Support Center